{"id":3353,"date":"2025-03-26T14:54:43","date_gmt":"2025-03-26T11:54:43","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3353"},"modified":"2025-03-26T15:23:19","modified_gmt":"2025-03-26T12:23:19","slug":"wave-life-sciences-announces-positive-data-forward-53-clinical-trial","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/wave-life-sciences-announces-positive-data-forward-53-clinical-trial\/","title":{"rendered":"Wave Life Sciences, DMD&#039;de FORWARD-53 Klinik Denemesinden WVE-N531 ile 48 Haftal\u0131k Dozlamadan Sonra \u00d6nemli Fonksiyonel Fayda ve Kas Hasar\u0131n\u0131n Geri D\u00f6nmesi Dahil Olumlu Veriler Duyurdu"},"content":{"rendered":"<p class=\"wp-block-paragraph\">RNA ila\u00e7lar\u0131n\u0131n insan sa\u011fl\u0131\u011f\u0131n\u0131 d\u00f6n\u00fc\u015ft\u00fcrme potansiyelini a\u00e7\u0131\u011fa \u00e7\u0131karmaya odaklanan klinik a\u015famadaki bir biyoteknoloji \u015firketi olan Wave Life Sciences, bug\u00fcn Duchenne kas distrofisi (DMD) olan ve ekzon 53 atlamaya uygun erkek \u00e7ocuklarda ara\u015ft\u0131r\u0131lan bir ekzon atlama oligon\u00fckleotidi olan WVE-N531&#039;in Faz 2 FORWARD-53 denemesinden olumlu veriler duyurdu. Analiz, her iki haftada bir dozlanan 10 mg\/kg WVE-N531 ile 48 haftal\u0131k tedaviden sonra ger\u00e7ekle\u015ftirildi.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">WVE-N531&#039;den elde edilen temel bulgular \u015funlard\u0131r:<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>48. haftada, onayl\u0131 herhangi bir distrofin restorasyon tedavisine k\u0131yasla g\u00f6zlenen en b\u00fcy\u00fck etkiyle, Y\u00fckselme S\u00fcresinde do\u011fal seyirle kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda 3,8 saniyelik istatistiksel olarak anlaml\u0131 ve klinik olarak anlaml\u0131 iyile\u015fme; NSAA dahil di\u011fer sonu\u00e7 \u00f6l\u00e7\u00fcmlerinde g\u00f6zlenen ek i\u015flevsel faydalar.<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Ekzon atlama ile kas sa\u011fl\u0131\u011f\u0131nda \u00f6nemli iyile\u015fmelerin ilk g\u00f6sterimi - inflamasyon ve nekrozdaki azalmalarla y\u00f6nlendirilen fibroziste istatistiksel olarak anlaml\u0131 azalma, rejeneratif kastan olgun kaslara ge\u00e7i\u015fle birlikte; kreatin kinazda ve dola\u015f\u0131mdaki inflamasyon biyobelirte\u00e7lerinde azalma.<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Distrofin ekspresyonu 24 ila 48 hafta aras\u0131nda sabitlendi ve ortalama 7.8% oldu; 5%&#039;nin \u00fczerindeki erkek \u00e7ocuklar\u0131nda ortalama distrofin 88% idi; WVE-N531 g\u00fcvenli ve iyi tolere edilmeye devam ediyor ve Ciddi Yan Etki g\u00f6r\u00fclmedi.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Wave Life Sciences&#039;nin Klinik Denemeleri<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">WVE-N531 ve Wave&#039;in 52, 51, 45 ve 44. ekzonlara y\u00f6nelik programlar\u0131, PN omurga kimyas\u0131 ve stereokimyasal kontrol de dahil olmak \u00fczere s\u0131n\u0131f\u0131n\u0131n en iyisi oligon\u00fckleotid kimyas\u0131ndan yararlanarak, antikor veya peptit konjugatlar\u0131na ihtiya\u00e7 duymadan sekt\u00f6rde lider kas iletimi ve g\u00fcc\u00fc sa\u011fl\u0131yor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Wave&#039;in PN kimyas\u0131 i\u00e7eren ekzon atlama adaylar\u0131 i\u00e7in klinik \u00f6ncesi veriler, kalp ve diyaframda iskelet kas\u0131na k\u0131yasla \u00f6nemli \u00f6l\u00e7\u00fcde daha y\u00fcksek distrofin ve ila\u00e7 konsantrasyonlar\u0131 da g\u00f6stermi\u015ftir. Toplu olarak, WVE-N531 art\u0131 Wave&#039;in ekzon 52, 51, 45 ve 44 programlar\u0131, DMD pop\u00fclasyonunun ~40%&#039;sini ele alacak ve yaln\u0131zca Amerika Birle\u015fik Devletleri&#039;nde &gt;$2,4 milyar toplam pazar f\u0131rsat\u0131n\u0131 temsil edecektir. Wave, 2026&#039;da di\u011fer ekzon atlama programlar\u0131 i\u00e7in birden fazla klinik deneme ba\u015fvurusu (CTA) sunmay\u0131 beklemektedir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Daha fazla bilgi edin: <a href=\"https:\/\/dmdwarrior.com\/tr\/next-generation-exon-skipping-therapies-for-duchenne-muscular-dystrophy\/\">Yeni Nesil Ekzon Atlama Terapileri<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Wave Life Sciences, a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced positive data from the Phase 2 FORWARD-53 trial of WVE-N531, which is an exon skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping. The [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3354,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[155,154,328,326,153,327],"class_list":["post-3353","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-exon-53","tag-exon-53-skipping","tag-exon-53-skipping-therapy","tag-forward-53","tag-wave-life-sciences","tag-wve-n531"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/3353","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=3353"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/3353\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/3354"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=3353"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=3353"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=3353"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}